2022 HKEX Biotech Listings Drop from Last Year’s Record High
After a record year of new biotech listings in 2021, the Hong Kong Stock Exchange (HKEX) has seen a significant drop-off in the first eight months of 2022. The exchange…
Address: 43rd Floor, Gloucester Tower, The Landmark, 15 Queen’s Road Central, Hong Kong
Tel: +852 2218 9100
Web: http://www.orrick.com/Offices/Hong-Kong/Pages/default.aspx
Hong Kong is uniquely positioned at the doorsteps of the world’s fastest growing major economy of the 21st century and the lawyers on Orrick’s China Team have been there since the first days those doors were opened. In 1972, Coudert Brothers was the first foreign law firm to open an office in Hong Kong and, in November 2005, the entire 25-lawyer office of Coudert joined Orrick, opening Orrick’s first of three China-focused offices. Orrick’s offices in Beijing and Shanghai opened in 2006 when most of Coudert’s lawyers in Beijing and Shanghai also joined Orrick. In addition to being first in Hong Kong, Coudert was the first foreign law firm to establish a permanent presence in Beijing (1979), the first foreign law firm to be approved by the Ministry of Justice to establish a law office in China (Beijing, 1992; with the receipt of license no. 001) and one of the first foreign law firms to open an office in Shanghai (2001).
For more than three decades, Orrick’s Hong Kong lawyers have been guiding the world’s most prominent businesses through many of the first and most complex commercial and financial transactions involving China, including:
* The Coca-Cola Company
* McDonald’s
* S.C. Johnson & Sons, Inc.
* Carrefour
* General Motors Corporation
* NEC Corporation
* Occidental Petroleum
Beyond China, the Hong Kong team’s experience extends throughout the Asia-Pacific region on significant transactions including the “London Club” of more than 60 commercial banks in a series of jumbo loans of more than $1.5 billion of U.S. dollar- and yen-denominated sovereign debt extended to the Republic of Indonesia; Telenor Ltd. (a Norwegian telecommunications company) in acquiring shares in two Thai telecommunications companies; foreign investors in a series of acquisitions and divestitures in the electric power generating sector in the Philippines; and structuring and advising many of the first hedge funds and private equity funds organized with investors from multiple jurisdictions for investment targets throughout the Asia-Pacific region.
International Reputation
The reputation of Orrick’s Hong Kong lawyers is well recognized by recent awards from leading global publications, including:
* M&A Deal of the Year
* Real Estate and Construction Deal of the Year
* Logistics Deal of the Year
Unique Qualifications
Orrick’s Hong Kong team is strongly positioned to assist local and international clients with sophisticated transactions that cross multiple jurisdictions. Orrick’s Hong Kong office provides clients with a unique combination of lawyers who are qualified in multiple jurisdictions, fluent in multiple languages, graduates of many of the world’s most well respected legal and business universities, experienced in business operations and management, and have served in government positions.
* Multiple Jurisdictions
Orrick’s Hong Kong lawyers have more than 30 years of experience handling corporate, commercial, securities, finance, litigation and arbitration matters under the laws of the multiple jurisdictions where local lawyers are qualified – Hong Kong, Australia, the United States, England and Wales.
* Multiple Language Capabilities
In addition to being qualified to practice in multiple jurisdictions, Orrick’s Hong Kong office also provides clients with lawyers who are fluent in multiple languages, including English, Cantonese, French, Korean, Mandarin and Putonghua.
* Legal Educations and Business Backgrounds
Lawyers in Orrick’s Hong Kong office have received graduate degrees (J.D./LL.B., LL.M., M.B.A., B.A. and B.S.) from well-known universities in the United States, the United Kingdom, Australia, China and Hong Kong, including Chinese University of Hong Kong, Columbia University, Fudan University (Shanghai), Harvard Law School, London School of Economics, New York Law School, Stanford Law School, University of California (Berkeley), University of Hong Kong, University of Melbourne, University of New South Wales, University of Southern California (Los Angeles), University of International Business and Economics (Beijing) and Yale College.
Orrick’s team of lawyers also includes lawyers with diverse backgrounds, including a lawyer who began advising foreign companies on China matters in 1980 as a Beijing-based business representative and consultant, a lawyer who practiced in California and Korea before moving to Hong Kong in 1993, a lawyer who worked for the Department of Justice of the Hong Kong Government, and a lawyer who held numerous Shenzhen-based management positions. The Hong Kong office is also staffed by Chinese and foreign consultants, legal assistants, trainee solicitors and translators.
Banking and Bank Regulatory Matters, Dispute Resolution, Emerging Companies and Venture Capital, Employment Law, Finance and Project Finance, Financial Markets, Intellectual Property, Internal Investigations, Life Sciences, Media and Entertainment, Mergers and Acquisitions, Private Equity, Investment Funds and Venture Capital, Real Estate Development and Finance, Restructuring, Securities, Tax
After a record year of new biotech listings in 2021, the Hong Kong Stock Exchange (HKEX) has seen a significant drop-off in the first eight months of 2022. The exchange…
Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and…
Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.…
Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has become Asia’s largest, and the world’s second-largest,…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong…
Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning…
Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative…
Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy…
Kelvin Chiu and Isabelle Dutry of Sanwa BioTech in Hong Kong highlight the critical importance of personalised fast-track diagnostics in countering the COVID-19 pandemic, the role that Asian firms have…
See our Cookie Privacy Policy Here